Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade ...

How Twist’s New Preclinical-Grade Plasmid DNA Preps Could Reshape the TWST Nucleic Acid Therapeutics Story

In early December 2025, Twist Bioscience launched research-grade Plasmid DNA Preps with animal origin-free and endotoxin-free options tailored to stringent preclinical study requirements. This move ...
Transparency Market Research

Plasmid Purification Market

Plasmid Purification Market to reach USD 6.6 Bn by 2035 at 12.3% CAGR, Driven by rising gene therapy demand, mRNA vaccines, ...
JSTOR Daily

A Virulence Plasmid in Escherichia coli Enterotoxigenic for Humans: Intergenetic Transfer and Expression

We studied the colonization-factor antigen I (CFA/I) fimbriae- and heat-stable enterotoxin (ST)-coding plasmid of enterotoxigenic Escherichia coli (strain H10407, serotype O78:H11) pathogenic for ...
FiercePharma

UPDATED: Thermo Fisher plots 74 layoffs at California plasmid manufacturing site as demand swings

Demand fluctuations have spurred Thermo Fisher Scientific to downsize at the plasmid DNA manufacturing facility the company opened a little less than three years ago, putting jobs on the chopping ...